Analystreport

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Cantor Fitzgerald from $10.00 to $5.00. They now have an "overweight" rating

Corvus Pharmaceuticals, Inc.  (CRVS) 
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corvuspharma.com